India Health Panel Urges No Trials For Drugs Four Years On Some Markets
This article was originally published in PharmAsia News
An Indian health ministry advisory committee has recommended skipping required clinical trials of drugs that have been on the market in some countries for at least four years.
You may also be interested in...
Sweden´s ecosystem for drug discovery and development is flourishing, seeded by academia, nurtured by incubators and funded from varied sources, 2020 report shows.
While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic eﬀectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.
Virtual trials could be the answer to limitations placed on innovation by the coronavirus pandemic and help companies formulate new health claims relevant to a new generation of consumers, argued IQVIA Consumer Health during a recent webinar.